Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

21 trials with published results (7%)

Research Maturity

114 completed trials (39% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.7%

8 terminated out of 295 trials

Success Rate

93.4%

+6.9% vs benchmark

Late-Stage Pipeline

6%

17 trials in Phase 3/4

Results Transparency

18%

21 of 114 completed with results

Key Signals

21 with results93% success

Data Visualizations

Phase Distribution

194Total
Not Applicable (66)
Early P 1 (29)
P 1 (65)
P 2 (17)
P 3 (8)
P 4 (9)

Trial Status

Completed114
Recruiting80
Unknown43
Not Yet Recruiting25
Withdrawn9
Terminated8

Trial Success Rate

93.4%

Benchmark: 86.5%

Based on 114 completed trials

Clinical Trials (295)

Showing 20 of 20 trials
NCT06948110RecruitingPrimary

Deciphering the Genetic Architecture of Autoimmune Diseases

NCT07513181Phase 2Not Yet Recruiting

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

NCT06736587Phase 1RecruitingPrimary

Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers

NCT01351545Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

NCT04663204Phase 2Recruiting

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

NCT07455578Phase 1RecruitingPrimary

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

NCT07613411Early Phase 1Not Yet RecruitingPrimary

Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases

NCT07604792Early Phase 1Enrolling By InvitationPrimary

FIT-(BCMA+CD19)-CAR-T Cells in Recurrent/Refractory Autoimmune Diseases Patients.

NCT04353609Completed

Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases

NCT07221565Phase 1Enrolling By Invitation

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT03651518Phase 2Completed

Personalized Therapies in Inflammatory Complex Disease

NCT04015596Phase 4Terminated

Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS

NCT04786821Not ApplicableCompleted

Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis

NCT03790293Phase 3CompletedPrimary

Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial

NCT07221890Not ApplicableActive Not RecruitingPrimary

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

NCT07586267Early Phase 1RecruitingPrimary

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

NCT07040774Recruiting

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

NCT05565248Phase 1Terminated

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

NCT06940869Enrolling By Invitation

Network to Understand Reproductive Rheumatology Registry

NCT06469788Not ApplicableRecruiting

Testimonials and Navigation in Rheumatology

Scroll to load more

Research Network

Activity Timeline